Studies have shown that high dosages of ESAs are strongly related to the risk of stroke, cardiovascular disease, cancer and, several clinical problems such as elevated blood pressure, anti-EPO effects, production of anti-EPO antibodies [6,7]. Here, EPO is linked to cardiovascular disorder.